Welcome to our dedicated page for Evofem Bioscienc news (Ticker: EVFM), a resource for investors and traders seeking the latest updates and insights on Evofem Bioscienc stock.
Evofem Biosciences, Inc. (OTC: EVFM) regularly issues news and updates focused on women’s sexual and reproductive health, its FDA-approved products, and its corporate strategy. Company press releases highlight developments around PHEXXI, a hormone-free, on-demand prescription contraceptive vaginal gel, and SOLOSEC, a single-dose oral antimicrobial treatment for bacterial vaginosis and trichomoniasis.
News items cover a range of topics, including quarterly and annual financial results, cost-of-goods initiatives, and progress on international expansion. For example, Evofem has announced licensing arrangements with Pharma 1 Drug Store in the Middle East and North Africa, regulatory submissions for PHEXXI and SOLOSEC in the United Arab Emirates, and steps toward commercialization in Gulf Cooperation Council states. These updates provide context on how the company is seeking to diversify and expand its revenue stream beyond the United States.
Evofem’s releases also describe marketing and educational campaigns such as the "Say Vagina" initiative, which the company presents as an effort to normalize clinical language and address stigma around vaginal health. Other news has detailed the impact of social media campaigns on traffic to the PHEXXI website, engagement from healthcare providers, and broader brand awareness.
In addition, investors can find news about corporate actions and governance, including information on a previously proposed merger with Aditxt, Inc. and its subsequent termination, reverse stock split authorization, and capital raises through notes and warrants. This news page aggregates such announcements so readers can follow product, regulatory, commercial, and corporate developments related to Evofem Biosciences and its EVFM stock symbol over time.
Evofem Biosciences (NASDAQ: EVFM) reported strong preliminary results for Q4 2021, achieving $3.5 million in net product sales, more than double Q3 sales. Key metrics included an 81% increase in dispensed Phexxi boxes and a 69% rise in total prescriptions filled. The company also reduced its net cash burn from $32 million in Q3 to approximately $17 million. Additionally, Evofem raised $5 million in non-dilutive capital in January 2022 to support ongoing initiatives. The CEO highlighted strong demand for Phexxi, projecting positive impacts from recently issued government guidance.
Evofem Biosciences (NASDAQ: EVFM) applauds recent guidance from HRSA and the U.S. Department of Labor, mandating coverage for FDA-approved contraceptives, including its product Phexxi, with no out-of-pocket costs for women. This guidance aims to enhance access to contraceptives under the Affordable Care Act, potentially benefiting millions of women. CEO Saundra Pelletier emphasized the positive impact on reducing unintended pregnancies and improving women's access to hormone-free birth control. The comprehensive coverage includes all FDA-approved contraceptives deemed medically necessary by healthcare providers.
Evofem Biosciences (NASDAQ: EVFM) announced its participation in the H.C. Wainwright BioConnect Virtual Conference from January 10–13, 2022. CEO Saundra Pelletier will present updates on the company's hormone-free contraceptive Phexxi® and its pipeline, including an ongoing Phase 3 clinical trial for EVO100 targeting chlamydia and gonorrhea, as well as a new Multipurpose Prevention Technology candidate for HIV. The presentation will be available on-demand starting 7:00 AM ET on January 10.
Evofem Biosciences (NASDAQ: EVFM) and Orion Biotechnology have announced a collaboration to evaluate the compatibility of Orion's CCR5 antagonist, OB-002, with Evofem's Phexxi vaginal gel. This partnership aims to develop a Multipurpose Prevention Technology (MPT) product for HIV prevention in women. The collaboration seeks results by Q3 2022 and will pursue funding for clinical trials if successful. WHO reports show a significant global need for effective HIV prevention methods. Phexxi, launched in September 2020, is a hormone-free contraceptive gel with ongoing trials for STI prevention.
Evofem Biosciences (NASDAQ: EVFM) announced optimistic projections for Q4 2021, expecting prescription growth for Phexxi to exceed 30,000 monthly, marking a 70% increase from Q3. The company anticipates that over 57,000 women will have chosen Phexxi by year-end 2021, with almost 24,000 in Q4 alone. Gross revenues are projected to rise by more than 50% from Q3. CEO Saundra Pelletier also noted a significant reduction in quarterly net cash burn by at least $10 million, highlighting a strong demand for non-hormonal birth control options.
Evofem Biosciences (NASDAQ: EVFM) announced the adjournment of its 2021 Special Meeting of stockholders, originally scheduled for December 8, 2021, to December 15, 2021. The meeting will be held at the company's corporate offices in San Diego, California. Stockholders of record as of November 5, 2021, are eligible to vote. There are no changes to the proposal previously outlined in the proxy statement filed with the SEC on November 9, 2021. The company continues to solicit proxies, and previously submitted proxies will be honored at the adjourned meeting.
Evofem Biosciences (NASDAQ: EVFM) announced a successful Type C meeting with the FDA regarding its product candidate, EVO100, aimed at preventing urogenital chlamydia and gonorrhea in women. These STIs currently lack FDA-approved preventive treatments. The pivotal Phase 3 trial, EVOGUARD, is enrolling 1,730 women across the U.S. Positive Phase 2B/3 AMPREVENCE trial results support EVO100's potential. The FDA has granted Fast Track designation and Qualified Infectious Disease Product status. Top-line data is expected in H2 2022, with potential FDA submission in Q1 2023.
Evofem Biosciences (NASDAQ: EVFM) has successfully extended the cumulative net sales covenant from its April 2020 Securities Purchase Agreement to June 30, 2023. This decision reflects investor confidence in the company's growth potential. Notably, Phexxi® prescriptions surged by 48% in Q3 2021 and saw a 30% rise in October 2021. The company anticipates improved gross-to-net revenue starting December 2021. The report emphasizes Evofem's focus on addressing unmet needs in women's health through innovative products.
Evofem Biosciences (NASDAQ: EVFM) announced that CEO Saundra Pelletier will participate in a fireside chat and hold one-on-one meetings at the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. The pre-recorded chat will be available on demand starting at 10:00 AM ET on November 22, 2021, for 90 days. Evofem focuses on innovative products for women's sexual and reproductive health, highlighted by their FDA-approved product, Phexxi®, a hormone-free contraceptive gel. For more details, visit evofem.investorroom.com/Piper2021.
Evofem Biosciences (NASDAQ: EVFM) reported its Q3 2021 financial results, highlighting a net product sales of $1.7 million and a notable 94% increase in new prescriptions for its hormone-free contraceptive, Phexxi, driven by the 'House Rules' DTC campaign featuring Annie Murphy. Total operating expenses rose by 5% to $45.1 million. The company expects to reduce operating expenses by $50 million in 2022. Despite a net loss of $74.1 million for the quarter, cash reserves were reported at $14.9 million.